WO2019227085A8 - Compositions bactériennes conçues et leurs utilisations - Google Patents

Compositions bactériennes conçues et leurs utilisations Download PDF

Info

Publication number
WO2019227085A8
WO2019227085A8 PCT/US2019/034069 US2019034069W WO2019227085A8 WO 2019227085 A8 WO2019227085 A8 WO 2019227085A8 US 2019034069 W US2019034069 W US 2019034069W WO 2019227085 A8 WO2019227085 A8 WO 2019227085A8
Authority
WO
WIPO (PCT)
Prior art keywords
bacterial compositions
designed
useful
designed bacterial
dysbiosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2019/034069
Other languages
English (en)
Other versions
WO2019227085A1 (fr
Inventor
Asuncion Martinez
Edward J. O'brien
Sheri Lynn SIMMONS
David Cook
Matthew R. HENN
Christopher B. Ford
Divya Balasubramanian
Ambar PIÑA
Liyang DIAO
Meghan Chafee
Marin VULIC
Madhumitha NANDAKUMAR
Sumon DATTA
Latta Jayaraman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seres Therapeutics Inc
Original Assignee
Seres Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020207036979A priority Critical patent/KR20210024481A/ko
Priority to EP19807289.4A priority patent/EP3801065A4/fr
Priority to JP2020565841A priority patent/JP2021524476A/ja
Priority to AU2019275125A priority patent/AU2019275125A1/en
Priority to BR112020023933-0A priority patent/BR112020023933A2/pt
Priority to CA3101184A priority patent/CA3101184A1/fr
Priority to CN201980048698.5A priority patent/CN112512342A/zh
Priority to MX2020012602A priority patent/MX2020012602A/es
Application filed by Seres Therapeutics Inc filed Critical Seres Therapeutics Inc
Priority to US17/058,351 priority patent/US20210196766A1/en
Publication of WO2019227085A1 publication Critical patent/WO2019227085A1/fr
Anticipated expiration legal-status Critical
Publication of WO2019227085A8 publication Critical patent/WO2019227085A8/fr
Priority to JP2024060904A priority patent/JP2024099549A/ja
Priority to US19/046,341 priority patent/US20250367242A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

L'invention concerne des compositions bactériennes qui sont utiles pour traiter et pour prévenir des complications ainsi que des effets secondaires associés à une maladie ou à un trouble tels que celles et ceux associé(e)s à une dysbiose du tube digestif. Les compositions bactériennes ici divulguées sont conçues pour présenter une ou plusieurs caractéristiques qui sont utiles dans le traitement de telles maladies et de tels troubles.
PCT/US2019/034069 2018-05-24 2019-05-24 Compositions bactériennes spécifiques et leurs utilisations Ceased WO2019227085A1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CN201980048698.5A CN112512342A (zh) 2018-05-24 2019-05-24 设计的细菌组合物及其用途
JP2020565841A JP2021524476A (ja) 2018-05-24 2019-05-24 設計された細菌組成物及びその使用
AU2019275125A AU2019275125A1 (en) 2018-05-24 2019-05-24 Designed bacterial compositions and uses thereof
BR112020023933-0A BR112020023933A2 (pt) 2018-05-24 2019-05-24 composições bacterianas projetadas e usos destas
CA3101184A CA3101184A1 (fr) 2018-05-24 2019-05-24 Compositions bacteriennes specifiques et leurs utilisations
MX2020012602A MX2020012602A (es) 2018-05-24 2019-05-24 Composiciones bacterianas dise?adas y usos de las mismas.
US17/058,351 US20210196766A1 (en) 2018-05-24 2019-05-24 Designed bacterial compositions and uses thereof
KR1020207036979A KR20210024481A (ko) 2018-05-24 2019-05-24 설계된 박테리아 조성물 및 이의 용도
EP19807289.4A EP3801065A4 (fr) 2018-05-24 2019-05-24 Compositions bactériennes spécifiques et leurs utilisations
JP2024060904A JP2024099549A (ja) 2018-05-24 2024-04-04 設計された細菌組成物及びその使用
US19/046,341 US20250367242A1 (en) 2018-05-24 2025-02-05 Designed bacterial compositions and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862676236P 2018-05-24 2018-05-24
US62/676,236 2018-05-24

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US17/058,351 A-371-Of-International US20210196766A1 (en) 2018-05-24 2019-05-24 Designed bacterial compositions and uses thereof
US19/046,341 Division US20250367242A1 (en) 2018-05-24 2025-02-05 Designed bacterial compositions and uses thereof

Publications (2)

Publication Number Publication Date
WO2019227085A1 WO2019227085A1 (fr) 2019-11-28
WO2019227085A8 true WO2019227085A8 (fr) 2021-03-18

Family

ID=68615645

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/034069 Ceased WO2019227085A1 (fr) 2018-05-24 2019-05-24 Compositions bactériennes spécifiques et leurs utilisations

Country Status (10)

Country Link
US (2) US20210196766A1 (fr)
EP (1) EP3801065A4 (fr)
JP (2) JP2021524476A (fr)
KR (1) KR20210024481A (fr)
CN (1) CN112512342A (fr)
AU (1) AU2019275125A1 (fr)
BR (1) BR112020023933A2 (fr)
CA (1) CA3101184A1 (fr)
MX (1) MX2020012602A (fr)
WO (1) WO2019227085A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2967077A4 (fr) 2013-03-15 2016-09-14 Seres Therapeutics Inc Compositions microbiennes et procédés associés basés sur un réseau
EP3444330B1 (fr) * 2016-06-14 2025-08-20 HealthBiome, Inc. Souche du genre agabaculum ayant des effets de prévention ou de traitement des maladies dégénératives du cerveau, et son utilisation
JP7168558B2 (ja) 2016-06-14 2022-11-09 ヴェダンタ バイオサイエンシーズ インコーポレーテッド Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置
EP3668527A1 (fr) 2017-08-14 2020-06-24 Seres Therapeutics, Inc. Compositions et méthodes de traitement de la maladie cholestatique
JP2021501185A (ja) 2017-10-30 2021-01-14 セレス セラピューティクス インコーポレイテッド 抗生物質耐性を処置するための組成物及び方法
EP3597202A1 (fr) * 2018-07-20 2020-01-22 Maat Pharma Composition du microbiote fécal destinée à être utilisée pour réduire l'inflammation induite par traitement
WO2020037271A1 (fr) 2018-08-17 2020-02-20 Vedanta Biosciences, Inc. Méthodes de diminution de la dysbiose et de restauration d'un microbiome
TW202126317A (zh) 2019-09-24 2021-07-16 美商普拉塔生技公司 用於治療發炎和免疫疾病之組成物和方法
WO2021057985A1 (fr) * 2019-09-27 2021-04-01 成都中医药大学 Utilisation de réactif pour détecter la teneur en calprotectine fécale dans la préparation d'un kit pour le dépistage de lésions utérines
CA3159711A1 (fr) * 2019-11-27 2021-06-03 Asuncion Martinez Compositions bacteriennes et leurs utilisations
CN116209750A (zh) * 2019-12-20 2023-06-02 西奈山伊坎医学院 用于治疗炎症性肠病的组合物和方法
IL271775A (en) * 2019-12-31 2021-06-30 Biomica Ltd Microbial consortium and uses thereof
WO2021163212A1 (fr) 2020-02-10 2021-08-19 Native Microbials, Inc. Compositions microbiennes et procédés d'utilisation pour l'entéropathie canine et la dysbiose
CN115052609A (zh) * 2020-02-12 2022-09-13 苏黎世大学 一种治疗癌症的细菌组合物
JP2023517235A (ja) * 2020-03-10 2023-04-24 フェデレーション バイオ インコーポレイテッド 疾患の処置のための微生物コンソーシアム
GB202007452D0 (en) 2020-05-19 2020-07-01 Microbiotica Ltd Threrapeutic bacterial composition
US20230233620A1 (en) * 2020-05-21 2023-07-27 Chan Zuckerberg Biohub, Inc. High-complexity synthetic gut bacterial communities
CA3188645A1 (fr) 2020-08-14 2022-02-17 Prolacta Bioscience, Inc. Compositions d'oligosaccharide de lait humain destinees a etre utilisees avec des bacteriotherapies
KR102700146B1 (ko) * 2020-09-28 2024-08-28 씨제이바이오사이언스 주식회사 미생물을 포함하는 염증성 질환 진단 또는 치료용 조성물
WO2022159711A1 (fr) * 2021-01-21 2022-07-28 Vedanta Biosciences, Inc. Compositions et méthodes de traitement de l'encéphalopathie hépatique
WO2022178193A2 (fr) * 2021-02-17 2022-08-25 Seres Therapeutics, Inc. Utilisation d'immunothérapie et de modulation du microbiome pour traiter le cancer
WO2022236365A1 (fr) * 2021-05-10 2022-11-17 Microba Ip Pty Ltd Composés et méthodes de traitement de maladies
NL2028324B1 (en) * 2021-05-28 2022-12-12 Caelus Pharmaceuticals B V Insulin-sensitizing agent and butyrate-producing bacterium
CN115806893B (zh) * 2021-09-13 2023-10-20 中国科学技术大学 普通拟杆菌及其组合物在辅助癌症免疫治疗中的应用
US20260027161A1 (en) * 2021-11-11 2026-01-29 Microba Ip Pty Ltd Bacterial strains for treating disease
CN114496279B (zh) * 2022-01-12 2022-08-30 广州保量医疗科技有限公司 菌群移植配型的排序方法、系统、计算机设备及存储介质
CN115852001A (zh) * 2022-11-23 2023-03-28 深圳海关动植物检验检疫技术中心 一种小麦病原菌检测方法及其应用
GB2627012A (en) * 2023-02-13 2024-08-14 Acad Medisch Ct Predictive biomarker of neonatal E.coli mediated sepsis
CN117797176B (zh) * 2024-03-01 2024-07-02 南京大学 双孢梭菌在制备治疗非酒精性脂肪性肝病药物中的应用和一种药物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004104175A2 (fr) * 2003-05-14 2004-12-02 University Of Georgia Research Foundation, Inc. Bacteries probiotiques et techniques
US8906668B2 (en) * 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
WO2014088982A1 (fr) * 2012-12-07 2014-06-12 Albert Einstein College Of Medicine Of Yeshiva University Traitement et prévention du dysfonctionnement de la barrière intestinale
CA2899925A1 (fr) * 2013-02-04 2014-08-07 Seres Therapeutics, Inc. Compositions et procedes pour l'inhibition de croissance bacterienne pathogene
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
US20160271189A1 (en) * 2015-03-18 2016-09-22 Whole Biome, Inc. Methods and compositions relating to microbial treatment and diagnosis of skin disorders
JP2018524354A (ja) * 2015-07-08 2018-08-30 セレス セラピューティクス インコーポレイテッド 大腸炎を処置する方法
US20190247447A1 (en) * 2015-11-24 2019-08-15 Seres Therapeutics, Inc. Designed bacterial compositions
WO2017160711A1 (fr) * 2016-03-14 2017-09-21 Holobiome, Inc. Modulation du microbiome intestinal pour traiter les troubles mentaux ou les maladies du système nerveux central
US11260083B2 (en) * 2016-03-15 2022-03-01 The Regents Of The University Of Michigan Compositions and methods for treating and preventing graft versus host disease
SG11201901726QA (en) * 2016-09-16 2019-03-28 Ubiome Inc Method and system for panel characterizations
JP7542946B2 (ja) * 2016-09-27 2024-09-02 ボード オブ リージェンツ， ザ ユニヴァーシティー オブ テキサス システム マイクロバイオームをモジュレートすることにより、免疫チェックポイント遮断療法を増強するための方法
JP2021501185A (ja) * 2017-10-30 2021-01-14 セレス セラピューティクス インコーポレイテッド 抗生物質耐性を処置するための組成物及び方法
AU2019393877A1 (en) * 2018-12-05 2021-06-17 Seres Therapeutics, Inc. Compositions for stabilizing bacteria and uses thereof

Also Published As

Publication number Publication date
US20210196766A1 (en) 2021-07-01
KR20210024481A (ko) 2021-03-05
US20250367242A1 (en) 2025-12-04
EP3801065A1 (fr) 2021-04-14
AU2019275125A1 (en) 2021-01-21
JP2021524476A (ja) 2021-09-13
BR112020023933A2 (pt) 2021-04-27
MX2020012602A (es) 2021-03-31
EP3801065A4 (fr) 2022-11-02
CN112512342A (zh) 2021-03-16
CA3101184A1 (fr) 2019-11-28
JP2024099549A (ja) 2024-07-25
WO2019227085A1 (fr) 2019-11-28

Similar Documents

Publication Publication Date Title
WO2019227085A8 (fr) Compositions bactériennes conçues et leurs utilisations
MX2022006407A (es) Composiciones bacterianas diseñadas y usos de estas.
IL291460A (en) Bacterial strains, their compositions and their use in the treatment of gastrointestinal disorders
MX2021010868A (es) Bacteria de la familia christensenellaceaeas en la prevencion y/o tratamiento de enfermedades inflamatorias cronicas y/o enfermedades gastrointestinales inflamatorias y/o canceres.
EP4484581A3 (fr) Souche d'akkermansia muciniphila eb-amdk19 et son utilisation
EP3584308A3 (fr) Compositions et procédés
PT4031157T (pt) Estirpes bacterianas, suas composições e sua utilização para o tratamento de perturbações gastrointestinais
MY186217A (en) Mixture of hmos
CA3045666A1 (fr) Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur de jak et dispositifs associes
EP4497474A3 (fr) Procédés de traitement de maladies rhumatismales à l'aide de composés à base de trimétazidine
WO2016172658A3 (fr) Régulateurs du microbiome et leurs utilisations associées
EP2440210A4 (fr) Procédés de traitement de troubles gastro-intestinaux
WO2016142445A3 (fr) Méthode de traitement d'une infection bactérienne
WO2017136795A8 (fr) Bactéries modifiées pour traiter des maladies associées au metabolisme du tryptophane
WO2014180889A8 (fr) Méthodes et compositions destinées à traiter le cancer
WO2017053868A8 (fr) Dérivés d'acide oléanolique modifié en c4 pour l'inhibition de l'il-17 et d'autres utilisations
WO2016200614A3 (fr) Bactéries modifiées en vue du traitement de maladies associées à l'hyperammoniémie
WO2017139697A8 (fr) Bactéries modifiées en vue du traitement de maladies associées à l'hyperammoniémie
WO2015143447A3 (fr) Méthodes de traitement de troubles neurologiques
ZA202000375B (en) Compounds for the prevention and treatment of medical disorders and uses thereof
WO2019169333A8 (fr) Composés afibrotiques, dispositifs et leurs utilisations
EP4548974A3 (fr) Modulateurs de somatostatine et leurs utilisations
EP3973586A4 (fr) Nouvelles compositions pharmaceutiques et méthodes de traitement de troubles mentaux, comportementaux et cognitifs
WO2017147130A3 (fr) Produits microbiens administrés directement pour la prévention de la maladie des crevettes
EP3810777A4 (fr) Compositions et procédés pour le traitement et la prévention de troubles neurologiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19807289

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3101184

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020565841

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020023933

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2019807289

Country of ref document: EP

Effective date: 20210111

ENP Entry into the national phase

Ref document number: 2019275125

Country of ref document: AU

Date of ref document: 20190524

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112020023933

Country of ref document: BR

Free format text: SOLICITA-SE APRESENTAR O COMPLEMENTO DO PEDIDO, TRADUZIDO E ADAPTADO AS NORMAS VIGENTES, CONFORME DEPOSITO INTERNACIONAL (RELATORIO DESCRITIVO E DESENHOS, SE HOUVER), EM ATENDIMENTO AO ART. 2O DA INSTRUCAO NORMATIVA INPI 031/13.

ENP Entry into the national phase

Ref document number: 112020023933

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20201124

WWW Wipo information: withdrawn in national office

Ref document number: 2019807289

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2020141299

Country of ref document: RU